Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

CD19 and CD10 double-target chimeric antigen receptor and application thereof

A chimeric antigen receptor and antigen technology, applied in the field of biomedicine, can solve problems such as tumor recurrence and poor treatment effect

Active Publication Date: 2021-03-19
广东昭泰细胞生物科技有限公司
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For example, tumor cells in some hematological tumors do not express CD19 molecules, but express CD10 molecules. Only CAR-T cells targeting CD19 molecules are not effective, and some patients have tumor recurrence after a period of time

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • CD19 and CD10 double-target chimeric antigen receptor and application thereof
  • CD19 and CD10 double-target chimeric antigen receptor and application thereof
  • CD19 and CD10 double-target chimeric antigen receptor and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] Example 1 Construction of CAR Molecular Carrier

[0054] In this example, anti-CD19 and anti-CD10 dual-target chimeric antigen receptor 19-10-CAR was constructed. The amino acid sequence is shown in SEQ ID NO:3, and the coding gene is shown in SEQ ID NO:6;

[0055] First, the whole gene is synthesized as SEQ ID NO: 6, and EcoRI and BamHI restriction sites and their protective bases are added at both ends;

[0056] Double-digest the coding gene with restriction endonucleases EcoRI and BamHI, incubate in a water bath at 37°C for 30 minutes, and use 1.5% agarose gel electrophoresis to recover the digested product containing sticky ends;

[0057] The digested product was ligated into the linearized pLVX-EF1-MCS plasmid (containing cohesive ends) that had been digested with EcoRI and BamHI, and the ligation system was shown in Table 1 to obtain a CAR containing dual targets targeting CD19 and CD10. Lentiviral vector encoding the gene.

[0058] Table 1

[0059] c...

Embodiment 2

[0061] Example 2 Lentiviral packaging

[0062] In this example, the lentiviral vector constructed in Example 1 is used for lentiviral packaging, using a four-plasmid system, and the steps are as follows:

[0063] Mix the helper plasmids gag / pol, Rev and VSV-G with the recombinant vector in proportion, add it to a certain volume of serum-free DMEM, mix it and let it stand for 15 minutes; add the above mixture to the cell culture flask lined with 293T cells , mixed gently, at 37°C, 5% CO 2 Cultivate in the cell incubator for 6 hours; after 6 hours, replace the fresh medium, continue to cultivate, and add 10mM sodium butyrate solution; after 72 hours, collect the lentivirus culture supernatant for purification and detection.

[0064] Recombinant vectors include lentiviral vectors containing genes encoding CARs targeting both CD19 and CD10, lentiviral vectors containing genes encoding CARs targeting CD19 single targets, and lentiviral vectors containing genes encoding CARs target...

Embodiment 3

[0065] Example 3 T cell activation and lentiviral transfection

[0066] Peripheral blood mononuclear cells (PBMC) were separated from whole blood using Ficoll density gradient centrifugation kit (GE Company), and after red blood cells were removed, T cells were sorted out using MACS Pan-T magnetic beads;

[0067] The sorted T cells were diluted with medium (AIM-V medium + 5% FBS + penicillin 100 U / mL + streptomycin 0.1 mg / mL) to a cell concentration of 2.5×10 6 pcs / mL for use;

[0068] CD2 / CD3 / CD28 T cell activation expansion kit (Miltenyi Company) was used to activate T cells, that is, the coated magnetic beads were mixed with T cells at a ratio of 1:2, and the final density of T cells was 5×10 6 piece / mL / cm 2 , after mixing, place at 37°C, 5% CO 2 The incubator was stimulated for 48 hours;

[0069] After T cells were activated for 48 hours, the beads were demagnetic, centrifuged at 300 g for 5 min, and the supernatant was removed. T cells were resuspended in fresh medium...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a CD19 and CD10 double-target chimeric antigen receptor and application thereof. The chimeric antigen receptor comprises an antigen binding domain, a transmembrane domain and asignal transduction domain, wherein the antigen binding domain comprises an anti-CD19 single-chain antibody and an anti-CD10 single-chain antibody. The anti-CD19 and CD10 double-target chimeric antigen receptor provided by the invention has small side effects and high safety; and constructed CAR-T cells are beneficial for avoiding an immune escape phenomenon and the possibility of disease recurrence is reduced.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and relates to a CD19 and CD10 dual-target chimeric antigen receptor and an application thereof. Background technique [0002] Chimeric antigen receptor (chimeric antigen receptor, CAR) is composed of tumor-associated antigen binding region, extracellular hinge region, transmembrane region and intracellular signal transduction region. Usually, the antibody single-chain fragment variable (single chain fragment variable, scFv) contained in the CAR molecule has a specific binding effect on the tumor-associated antigen (tumor associated antigen, TAA). Cytoplasmic domain coupling. Chimeric antigen receptor T-cell immunotherapy (CAR-T) has become one of the most promising tumor immunotherapies. [0003] At present, the new generation of CAR-T therapy targeting CD19 has achieved great success in the treatment of hematological tumors. However, due to the impact of tumor immune escape, it is not eff...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00C12N15/62C12N15/867C12N5/10A61K39/00A61P35/00
CPCC07K16/2803C07K16/2896C07K14/7051C12N15/86C12N5/0636A61K39/001112A61K39/001129A61P35/00C07K2317/622C07K2319/03C07K2319/33C07K2319/74C12N2740/15043C12N2800/107C12N2510/00A61K2039/5156
Inventor 汤朝阳秦乐吴迪冯世忠冯嘉昆杨乐旋其他发明人请求不公开姓名
Owner 广东昭泰细胞生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com